Datroway First to Improve Survival in Metastatic TNBC

AstraZeneca and Daiichi Sankyo reported that their TROP2‑directed antibody‑drug conjugate DATROWAY (datopotamab deruxtecan‑dlnk) produced statistically significant and clinically meaningful improvements in overall survival and progression‑free survival versus chemotherapy as first‑line treatment for metastatic triple‑negative breast cancer patients ineligible for immunotherapy in the Phase III TROPION‑Breast02 trial. The companies said DATROWAY is the first therapy to show an overall survival benefit versus chemotherapy in this specific patient population, which they estimate represents roughly 70% of metastatic TNBC cases. The safety profile was consistent with prior DATROWAY studies, and detailed efficacy and safety data will be presented at a medical meeting and shared with regulators for review. DATROWAY was discovered by Daiichi Sankyo and is jointly developed with AstraZeneca; it is already approved in more than 35 countries for hormone receptor‑positive, HER2‑negative breast cancer and is being evaluated in lung cancer programs.